Apolipoprotein E 4 allele, AD pathology, and the clinical expression of Alzheimer's disease

Rush Alzheimer's Disease Center, Chicago, Illinois 60612, USA.
Neurology (Impact Factor: 8.29). 01/2003; 60(2):246-52. DOI: 10.1212/01.WNL.0000042478.08543.F7
Source: PubMed


To test the hypothesis that the APOE epsilon4 allele is associated with the clinical manifestations of AD through an association with the pathologic hallmarks of disease.
Participants were older Catholic nuns, priests, and brothers who agreed to annual neurologic and neuropsychological evaluation for AD and other common neurologic conditions and brain autopsy at the time of death. There were 77 persons without dementia and 51 with probable AD; 38 participants had one or more epsilon4 alleles.
In logistic regression analyses, controlling for age, sex, and education, the epsilon4 allele was strongly associated with the likelihood of clinical AD (odds = 3.46, 95% CI = 1.44 to 8.33). However, controlling for the effect of AD pathology, the association of the epsilon allele with clinical AD was reduced by >50% and was no longer significant (odds = 1.58, 95% CI = 0.56 to 4.43). Similarly, in linear regression analyses, controlling for age, sex, and education, the epsilon4 allele was strongly associated with level of cognitive function proximate to death (regression coefficient = -0.477, p = 0.005). However, after controlling for the effect of AD pathology, the association of the epsilon4 allele with level of cognition was reduced by >80% and was no longer significant (regression coefficient = -0.093). Similar results were found in analyses using separate measures of neuritic plaques, diffuse plaques, and neurofibrillary tangles, and in analyses of five different cognitive systems (episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability).
The APOE epsilon4 allele appears to be associated with the clinical manifestations of AD through an association with the pathologic hallmarks of AD rather than another mechanism.

10 Reads
  • Source
    • "If Aβ is an initiator of the long and complex cascade of pathologic alterations that take place in AD, then a multitude of downstream effectors and modifying factors (including genetics, other medical conditions, and environment) would have a profound effect on the rate and severity of disease progression (Korf et al., 2004; Bennett et al., 2006; Barberger-Gateau et al., 2007; Ngandu et al., 2007; van Vliet et al., 2009; Chang et al., 2010; Rusanen et al., 2011; Reijmer et al., 2012; Tolppanen et al., 2013; Virta et al., 2013). In this scenario one would predict that Aβ would correlate more poorly (but still significantly) with cognitive decline while more downstream effectors (e.g., synaptic loss) would correlate better (Bennett et al., 2003, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulation of the amyloid-beta (Aβ) peptide is a central factor in Alzheimer's disease (AD) pathogenesis as supported by continuing evidence. This review concisely summarizes this evidence supporting a critical role for Aβ in AD before discussing the clearance of this peptide. Mechanisms of clearance of Aβ are critical for preventing pathological elevations in Aβ concentration. Direct degradation of Aβ by endopeptidases has emerged as one important pathway for clearance. Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are "NEP-like") as these inhibitors induce a dramatic increase in Aβ levels in rodents. This review will focus on neprilysin-2 (NEP2), a NEP-like endopeptidase which cooperates with NEP to control Aβ levels in the brain. The evidence for the involvement of NEP2 in AD is discussed as well as the therapeutic relevance with regards to gene therapy and the development of molecular markers for the disease.
    Full-text · Article · Aug 2014 · Frontiers in Aging Neuroscience
  • Source
    • "Specifically, cholesterol forms the core of the neuritic plaques that characterize AD, and it is thought that a primary role of the amyloid precursor protein (APP) is to clear excess cholesterol from the brain (Puglielli et al., 2003). The most established genetic risk factor for AD is the apolipoprotein E (APOE)-ε4 allele, which has been associated with nearly a doubling in the risk of developing AD (Bennett et al., 2003; Evans et al., 1997). ApoE encodes one of several proteins involved in cholesterol transport between the gut, liver, and peripheral tissues and they are the predominant cholesterol transport proteins in the brain. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This is a qualitative review of the evidence linking dietary fat composition to the risk of developing dementia. The review considers laboratory and animal studies that identify underlying mechanisms as well as prospective epidemiologic studies linking biochemical or dietary fatty acids to cognitive decline or incident dementia. Several lines of evidence provide support for the hypothesis that high saturated or trans fatty acids increase the risk of dementia and high polyunsaturated or monounsaturated fatty acids decrease risk. Dietary fat composition is an important factor in blood-brain barrier function and the blood cholesterol profile. Cholesterol and blood-brain barrier function are involved in the neuropathology of Alzheimer's disease, and the primary genetic risk factor for Alzheimer's disease, apolipoprotein E-ε4, is involved in cholesterol transport. The epidemiologic literature is seemingly inconsistent on this topic, but many studies are difficult to interpret because of analytical techniques that ignored negative confounding by other fatty acids, which likely resulted in null findings. The studies that appropriately adjust for confounding by other fats support the dietary fat composition hypothesis.
    Full-text · Article · May 2014 · Neurobiology of Aging
  • Source
    • "The diagnosis of AD was made in accordance with established criteria by the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) (McKhann et al., 1984). The diagnosis of MCI referred to individuals not found to have dementia by the examining physician but rated as impaired on neuropsychological tests by a neuropsychologist (Bennett et al., 2003). The median interval from last clinical evaluation to autopsy was 7.7 months, and the median interval from last valid global cognitive score to autopsy was 7.9 months. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Corpora amylacea (CA) are glycoproteinaceous (predominantly glial and extracellular) inclusions that accumulate in normal aging brain and, to a greater extent, in Alzheimer disease (AD). Previous pharmacological evidence suggested that up-regulation of endogenous heme oxygenase-1 (HO-1) in astrocytes promotes transformation of normal mitochondria to CA-like inclusions. Here, we determined whether 1) HMOX1 transfection fosters the accumulation of CA-like inclusions in cultured rat astroglia; 2) the HMOX1 transgene promotes CA formation in the brains of aging GFAP.HMOX1 mice; and 3) brain mitochondrial damage and CA biogenesis are augmented in persons with mild cognitive impairment (MCI), a harbinger of AD. Methods: CA were ascertained in (i) neonatal rat astroglia transfected with flag-tagged human HO-1 cDNA, (ii) brain sections derived from 19month-old GFAP.HMOX1 and wild-type (WT) mice, and (iii) post-mortem hippocampal sections from individuals with mild (MCI) and no cognitive impairment (NCI) after staining with PAS or antisera against HO-1, ubiquitin (Ub), manganese superoxide dismutase (MnSOD), and α-synuclein or tyrosine hydroxylase (TH). Results: HMOX1 transfection induced cytoplasmic vacuolation and the accumulation of PAS+ inclusions in cultured astroglia. Numerous CA-like inclusions stained with PAS and immunoreactive for HO-1, Ub and MnSOD were observed in the brains of GFAP.HMOX1 mice, but were rarely encountered in age-matched, WT controls. Numbers of HO-1-positive CA were significantly increased in certain hippocampal strata of MCI subjects relative to NCI preparations. MnSOD and Ub proteins co-localized to CA in both the control and MCI specimens. Conclusions: HO-1 promotes mitochondrial damage and CA biogenesis in astrocyte cultures and in the intact aging brain. CA formation is enhanced in the MCI hippocampus and thus occurs relatively early in the pathogenesis of AD. Glial HO-1 suppression may attenuate bioenergetic failure and slow disease progression in AD and other neurodegenerative conditions featuring accelerated accumulation of CA.
    Full-text · Article · Jan 2014 · Experimental Neurology
Show more